OPEN framework extended to a wider range of medicines

20 July 2023 - EMA has expanded the scope of the OPEN initiative from COVID-19 vaccines and treatments to a ...

Read more →

Big pharma may have to reveal government deals in WHO's draft pandemic rules

17 November 2022 - Pharmaceutical companies could be made to disclose prices and deals agreed for any products they make ...

Read more →

Prescription medicines: applications under evaluation

24 August 2022 - The TGA has updated its list of applications for new medicines or new uses for existing ...

Read more →

Former FDA officials call for more transparency for drug approvals

15 June 2022 - The US FDA needs to take a more proactive approach in combatting misinformation and communicating decisions to ...

Read more →

Assessment of public opinion on transparency at the US Food and Drug Administration

18 February 2022 - Historically, the US FDA has considered much of the oversight of clinical trials, interactions with companies, and ...

Read more →

COVID-19 vaccines and treatments: we must have raw data, now

19 January 2022 - Data should be fully and immediately available for public scrutiny ...

Read more →

Optimising the data available via Health Canada’s clinical information portal

23 August 2021 - Through its Public Release of Clinical Information initiative, Health Canada has provided public access to a vast ...

Read more →

International regulators and WHO call for wider public access to clinical data

7 May 2021 - The International Coalition of Medicines Regulatory Authorities and the World Health Organisation are urging pharmaceutical companies to ...

Read more →

FDA scraps another last-minute Trump-era policy

30 April 2021 - The US FDA on Friday revoked a policy issued in the final days of the Trump ...

Read more →

EMA COVID-19 assessments ‘OPEN’ to non-EU regulators

4 February 2021 - EMA is piloting a new ‘OPEN’ initiative to increase international collaboration on the evaluation of COVID-19 vaccines ...

Read more →

Extra transparency measures for COVID-19 vaccines and therapeutics

30 October 2020 - Today the EMA has implemented two further extra transparency measures for COVID-19 medicines, by publishing both ...

Read more →

New transparency measures for prescription medicines

9 October 2020 - The Australian Government has given approval to proceed with two measures to enhance transparency for prescription ...

Read more →

FDA discloses vaccine guidelines blocked by White House

7 October 2020 - The FDA has laid out its safety standards for developers of COVID-19 vaccines after the White House ...

Read more →

EU regulators fully uphold transparency and independence standards for COVID-19 treatments and vaccines

5 October 2020 - The EMA has re-affirmed today that it will uphold its long-standing commitment to independence and transparency ...

Read more →

Increase transparency at the FDA: we need sunlight to fight the pandemic

29 September 2020 - The FDA has issued a number of contentious decisions during the COVID-19 pandemic related to investigational ...

Read more →